Incannex Healthcare Inc. Business Combination, Acquisition Related Costs
Incannex Healthcare Inc. (IXHL) reported Business Combination, Acquisition Related Costs of $35.30 million for the 12-month period ending 2024-06-30, per its 10-K filed 2024-09-30.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:BusinessCombinationAcquisitionRelatedCosts · last filed 2024-09-30
- Incannex Healthcare Inc. business combination, acquisition related costs for fiscal 2024 was $35.30M.
| Period end | Business Combination, Acquisition Related Costs 12 month |
|---|---|
| 2024-06-30 | $35.30M 10-K · filed 2024-09-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B |